Spero $105M royalty financing
Analysis based on 9 articles · First reported Jul 14, 2026 · Last updated Jul 14, 2026
The financing strengthens Spero's balance sheet with non-dilutive capital, reducing near-term dilution risk for shareholders. The deal also validates the value of Utebzi and supports Spero's pivot to immunology, potentially boosting investor confidence.
Spero Therapeutics announced a $105 million non-recourse non-dilutive royalty financing transaction with Healthcare Royalty (HCRx), a business of KKR. Under the agreement, HCRx will receive a portion of future milestone and royalty payments from sales of Utebzi (tebipenem pivoxil), which was recently approved by the FDA for complicated urinary tract infections. The proceeds will support Phase 2 development of SP001, an anti-CD40L monoclonal antibody in-licensed from Innovent Biologics. Spero updated its cash runway guidance into the second half of 2029. The transaction unlocks immediate value from Utebzi milestones and royalties while preserving long-term upside for Spero.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard